|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Braza MS and Klein B: Anti-tumour
immunotherapy with Vγ9Vδ2 T lymphocytes: From the bench to the
bedside. Br J Haematol. 160:123–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dhar S and Chiplunkar SV: Lysis of
aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T
cells. Cancer Immun. 10:102010.PubMed/NCBI
|
|
4
|
Wu YL, Ding YP, Tanaka Y, Shen LW, Wei CH,
Minato N and Zhang W: γδ T cells and their potential for
immunotherapy. Int J Biol Sci. 10:119–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bouet-Toussaint F, Cabillic F, Toutirais
O, Le Gallo M, Thomas de la Pintière C, Daniel P, Genetet N,
Meunier B, Dupont-Bierre E, Boudjema K and Catros V: Vgamma9Vdelta2
T cell-mediated recognition of human solid tumors. Potential for
immunotherapy of hepatocellular and colorectal carcinomas. Cancer
Immunol Immunother. 57:531–539. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toutirais O, Cabillic F, Le Friec G, Salot
S, Loyer P, Le Gallo M, Desille M, de La Pintière CT, Daniel P,
Bouet F and Catros V: DNAX accessory molecule-1 (CD226) promotes
human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T
cells. Eur J Immunol. 39:1361–1368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cabillic F, Toutirais O, Lavoué V, de La
Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H,
Mönkkönen J, Boudjema K, et al: Aminobisphosphonate-pretreated
dendritic cells trigger successful Vgamma9Vdelta2 T cell
amplification for immunotherapy in advanced cancer patients. Cancer
Immunol Immunother. 59:1611–1619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kondo M, Sakuta K, Noguchi A, Ariyoshi N,
Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, et al:
Zoledronate facilitates large-scale ex vivo expansion of functional
gammadelta T cells from cancer patients for use in adoptive
immunotherapy. Cytotherapy. 10:842–856. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nicol AJ, Tokuyama H, Mattarollo SR, Hagi
T, Suzuki K, Yokokawa K and Nieda M: Clinical evaluation of
autologous gamma delta T cell-based immunotherapy for metastatic
solid tumours. Br J Cancer. 105:778–786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rincon-Orozco B, Kunzmann V, Wrobel P,
Kabelitz D, Steinle A and Herrmann T: Activation of V gamma 9V
delta 2 T cells by NKG2D. J Immunol. 175:2144–2151. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pang DJ, Neves JF, Sumaria N and
Pennington DJ: Understanding the complexity of γδ T-cell subsets in
mouse and human. Immunology. 136:283–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bauer S, Groh V, Wu J, Steinle A, Phillips
JH, Lanier LL and Spies T: Activation of NK cells and T cells by
NKG2D, a receptor for stress-inducible MICA. Science. 285:727–729.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kunzmann V and Wilhelm M: Anti-lymphoma
effect of gammadelta T cells. Leuk Lymphoma. 46:671–680. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Todaro M, D'Asaro M, Caccamo N, Iovino F,
Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G,
Salerno A, et al: Efficient killing of human colon cancer stem
cells by gammadelta T lymphocytes. J Immunol. 182:7287–7296. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE
and Ansell SM: Attenuation of CD8(+) T-cell function by
CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.
Cancer Res. 66:10145–10152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mempel TR, Pittet MJ, Khazaie K, Weninger
W, Weissleder R, von Boehmer H and von Andrian UH: Regulatory T
cells reversibly suppress cytotoxic T cell function independent of
effector differentiation. Immunity. 25:129–141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B,
Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T
cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi Y, Hong WH, Wang JX, Cai XY, Li YW,
Zhou J, Cheng YF, Jin JJ, Fan J and Qiu SJ: The functional
impairment of HCC-infiltrating γδ T cells, partially mediated by
regulatory T cells in a TGFβ- and IL-10-dependent manner. J
Hepatol. 58:977–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang
Z, Wang C, Zhang Z and Xia W: γδT17 cells promote the accumulation
and expansion of myeloid-derived suppressor cells in human
colorectal cancer. Immunity. 40:785–800. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X,
Shi L, Wu D, Dong C and Liu H: IL-17A produced by γδ T cells
promotes tumor growth in hepatocellular carcinoma. Cancer Res.
74:1969–1982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Llovet JM, Di Bisceglie AM, Bruix J,
Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M,
Talwalkar J, et al: Design and endpoints of clinical trials in
hepatocellular carcinoma. J Natl Cancer Inst. 100:698–711. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilhelm M, Kunzmann V, Eckstein S, Reimer
P, Weissinger F, Ruediger T and Tony HP: Gammadelta T cells for
immune therapy of patients with lymphoid malignancies. Blood.
102:200–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dieli F, Vermijlen D, Fulfaro F, Caccamo
N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia
N, et al: Targeting human{gamma}delta} T cells with zoledronate and
interleukin-2 for immunotherapy of hormone-refractory prostate
cancer. Cancer Res. 67:7450–7457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Santini D, Martini F, Fratto ME, Galluzzo
S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L, Manavalan
JS, et al: In vivo effects of zoledronic acid on peripheral T
lymphocytes in early breast cancer patients. Cancer Immunol
Immunother. 58:31–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bennouna J, Bompas E, Neidhardt EM,
Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert
M, et al: Phase-I study of innacell gammadelta, an autologous
cell-therapy product highly enriched in gamma9delta2 T lymphocytes,
in combination with IL-2, in patients with metastatic renal cell
carcinoma. Cancer Immunol Immunother. 57:1599–1609. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oberg HH, Kellner C, Peipp M, Sebens S,
Adam-Klages S, Gramatzki M, Kabelitz D and Wesch D: Monitoring
circulating γδ T cells in cancer patients to optimize γδ T
cell-based immunotherapy. Front Immunol. 5:6432014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dieli F, Gebbia N, Poccia F, Caccamo N,
Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano
C, et al: Induction of gammadelta T-lymphocyte effector functions
by bisphosphonate zoledronic acid in cancer patients in vivo.
Blood. 102:2310–2311. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ismaili J, Olislagers V, Poupot R, Fournie
JJ and Goldman M: Human gammadelta T cells induce dendritic cell
maturation. Clin Immunol. 103:296–302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Conti L, Casetti R, Cardone M, Varano B,
Martino A, Belardelli F, Poccia F and Gessani S: Reciprocal
activating interaction between dendritic cells and
pamidronate-stimulated gammadelta T cells: Role of CD86 and
inflammatory cytokines. J Immunol. 174:252–260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Devilder MC, Maillet S, Bouyge-Moreau I,
Donnadieu E, Bonneville M and Scotet E: Potentiation of
antigen-stimulated V Gamma 9V delta 2 T cell cytokine production by
immature dendritic cells (DC) and reciprocal effect on DC
maturation. J Immunol. 176:1386–1393. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
|
|
32
|
Li J, Lau GK, Chen L, Dong SS, Lan HY,
Huang XR, Li Y, Luk JM, Yuan YF and Guan XY: Interleukin 17A
promotes hepatocellular carcinoma metastasis via NF-kB induced
matrix metalloproteinases 2 and 9 expression. PLoS One.
6:e218162011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity and immune correlates
of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
